CHEK2 and cancer: Since the frequency of carriers may vary depending on the population, and different mutations may be associated with different cancer risks, more studies—in different populations—are needed to establish a complete range of risks associated with CHEK2 founder alleles and to estimate the appropriated risks related to several mutations for different cancer sites.